在平行合成条件下深入研究了卤代(杂)芳烃磺酰卤胺化物的化学选择性,并确定了该方法的范围和局限性。结果表明, SN Ar反应性磺酰卤通常在第一步中进行磺酰胺合成;如果SN Ar活性中心具有足够的反应性,则第二次胺化也是可能的。相反,带有芳基化部分的磺酰氟在适当的控制下在后一个反应中心发生选择性转化。进一步的硫-氟化物交换(SuFEx)也是可能的,这对于某些磺酰卤类特别有价值。开发的两步并行双胺化方案提供了对 66.7 亿个化合物的合成可处理 REAL 型化学空间的访问(预期合成成功率 76%)。
An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.
An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.